Effect of converting enzyme inhibition on the course of adriamycininduced nephropathy. The effect of the converting enzyme inhibitor (CE!) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis. Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria, blood pressure, and plasma albumin concentration. Groups 1 and 3 remained untreated while groups 2 and 4 received enalapril. Groups I and 2 underwent micropuncture studies after 10 days. These short-term studies showed that enalapril reduced arterial blood pressure (101 2 vs. 124 3 mm Hg, group 2 vs. I, P < 0.05) and glomerular capillary pressure (54 I vs. 61 2 mm Hg, P < 0.05) without reducing albuminuria (617 50 vs. 570 47 mg/day) or GFR (1.03 0.04 vs. 1.04 0.11 mI/mm). Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis. Chronic enalapril treatment reduced blood pressure without reducing albuminuria in group 4. Untreated group 3 rats exhibited a progressive reduction in GFR (0,35 0.08 mI/mm at 4 months, 0.27 0.07 ml/min at 6 months). Enalapril treatment blunted but did not prevent reduction in GFR in group 4 (0.86 0.15 mI/mm at 4 months, 0.69 0.13 ml/min at 6 months, both P < 0.05 vs. group 3). Reduction in GFR was associated with the development of glomerular sclerosis in both treated and untreated rats. Enalapril treatment limited but did not prevent glomerular sclerosis (sclerosis scores group 3 vs. 4: 29 5 vs. 10 Sat 4 months, P < 0.05; 54 5 vs. 37 8 at 6 months, P = NS). These results show that CE! treatment does not reduce albuminuria and offers limited protection against progressive loss of renal function in adriamycin nephrosis.
Recent studies have related progressive glomerular injury to elevated glomerular capillary pressure in rats with reduced nephron number and in rats with diabetes mellitus. Treatment with a converting enzyme inhibitor has been shown to reduce glomerular capillary pressure and to prevent development of albuminuria and glomerular sclerosis in these two models of renal disease [1] [2] [3] . Treatment with converting enzyme inhibitors has also been shown to reduce albuminuria in rats with passive Heymann nephritis [4] . The current study was designed to assess the effect of converting enzyme inhibitor treatment in rats with adriamycin-induced nephropathy. The glomerular injury induced by adriamycin is characterized by sustained heavy proteinuria and by glomerular capillary hypertension [5] [6] [7] . Chronic studies have shown that heavy proteinuria is associated with eventual development of widespread glomerular sclerosis and reduction of the glomerular filtration rate in this disease model [8] [9] [10] . In the current study we sought first to show whether administration of a converting enzyme inhibitor would reduce glomerular capillary pressure and albuminuria in rats with established adnamycin nephrosis. Second, we sought to establish whether chronic treatment with a converting enzyme inhibitor would prevent development of glomerular sclerosis and renal insufficiency in this model of the nephrotic syndrome.
Methods
Male Munich-Wistar rats weighing 226 to 258 grams received a single dose of adriamycmnR (doxorubicin HC1), 3.3 mg/kg, via tail vein injection under brevital anesthesia. Previous studies have shown that heavy proteinuria is established four weeks after administration of adnamycin [5, 61 . Baseline measurements were therefore obtained at this time point, and the nephrotic rats were divided into four groups with similar mean values for systolic blood pressure, urinary albumin excretion rate, and plasma albumin concentration. Groups 1 and 3 thereafter received no specific therapy while groups 2 and 4 were given the converting enzyme inhibitor enalapril, 400 mg/liter in the drinking water. All animals had unrestricted access to standard rat chow containing -24% protein by weight.
Short-term effect of converting enzyme inhibition
The short-term effect of converting enzyme inhibition in rats with established adriamycin nephrosis was assessed in untreated group 1 rats (N = 8) and enalapril-treated group 2 rats (N = 8). Repeat measurements of albumin excretion rate, blood pressure, and plasma albumin concentration were obtained 10 days after baseline. Following these measurements, micropuncture studies were performed to relate the effect of CE! treatment on albuminuria and blood pressure to its effect on glomerular hemodynamic function.
table. A PESO catheter was inserted into the left femoral artery
to obtain arterial blood samples and record mean arterial pressure (AP). A was continuously monitored with an elec-tronic pressure transducer connected to a direct-writing pressure recorder. After tracheostomy, PESO catheters were inserted into the jugular veins for infusion of rat plasma, inulin, and saline, and the left ureter was catheterized with PE1O tubing. After insertion of the jugular catheters, plasma was infused in an amount equal to 1% body weight over 40 to 45 minutes, followed by an infusion of -0.5 mllhr for the duration of the experiment. Plasma for infusion was obtained by mixing aliquots of plasma from nephrotic donor rats and normal donor rats to provide an albumin concentration equal to that of the animal being studied. Nephrotic donor rats were Sprague-Dawley rats given adriamycin, 3 mglkg i.v., four weeks prior to sacrifice. Saline was infused in an amount equal to 4% body weight over 80 to 110 minutes followed by a reduction in infusion rate to 2.4 mI/hr for the remainder of each experiment. At this point tritiated methoxy-inulin was added to the saline to obtain an infusion rate of -110 CiIhr following a loading dose of-SO mCi.
Micropuncture studies were then carried out during two to three 30-to 40-minute clearance periods. In each period a 200 jsl arterial blood sample was drawn for determination of arterial hematocrit (Hct) and plasma inulin and total protein concentration. A simultaneous 100 d blood sample was obtained from an indwelling left renal vein catheter to determine filtration fraction by comparison of arterial and renal vein inulin concentrations. Time averaged hydraulic pressure measurements were obtained in surface glomerular capillaries (2 to 4 determinations per rat), proximal tubules (3 to 7 determinations), and efferent arterioles (3 to 4 determinations) with a continuous recording servo-null micropipette transducer system (Model V. Instrumentation for Physiology and Medicine, San Diego, California, USA) coupled to the second channel of the pressure recorder. Timed (4 mm) samples of tubule fluid were obtained from superficial proximal tubules of three to five nephrons to determine the single nephron glomerular filtration rate (SNGFR).
The pressor responses to 25, 50, 100 and 200 ng i.v. bolus doses of angiotensin I were measured following micropuncture study to verify effective converting enzyme inhibition in enalapriltreated rats.
Chronic effect of converting enzyme inhibition
The effect of converting enzyme inhibition on the course of adriamycin-induced nephropathy was assessed in untreated group 3 rats (N = 26) and enalapril-treated group 4 rats (N = 21) . In this chronic study the dose of enalapril was increased to 600 mg/liter in two rats after one month and to 500 mg/liter in four rats after four months. Repeat measurements of systolic blood pressure and albuminuria were obtained bimonthly. In approximately half of these rats (N = 10 group 3 rats and N = 9 group 4 rats) glomerular filtration rate was measured and kidney tissue obtained for morphologic analysis after four months. Similar studies were performed in the remaining animals after six months.
Functional studies. Rats were prepared as described for micropuncture studies. Glomerular filtration rate was measured over two 30-minute clearance periods. GFR was not measured in two group 3 rats studied at six months.
Morphologic studies. Following measurement of the GFR, kidneys were fixed by retrograde aortic perfusion at measured arterial pressure with 1.25% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4). After perfusion fixation, the weight of the left kidney was measured and two 2 mm thick coronal sections through the midportion of the kidney were post-fixed in buffered 4% formaldehyde solution. Paraffin sections were stained by the Periodic Acid Schiff technique and with hematoxylin and eosin. A modification of the scoring system of Raij, Azar and Keane [111 was used to evaluate the degree of glomerular injury in each animal. Each glomerulus in a single section was assigned a score from 0 to 3+ according to the portion of the tuft manifesting sclerotic changes. A score of 0 was assigned to glomeruli without sclerotic changes, a score of 1 to glomeruli with less than one-third of the tuft showing sclerotic changes, a score of 2 to glomeruli with between one-third and two-thirds of the tuft showing sclerotic changes, and a score of 3 to glomeruli with sclerotic changes in all areas of the tuft. The glomerular injury score for each animal was then calculated as:
where F1 is the percentage of glomeruli in that animal with a given score i. This analysis was performed on an average of 120 glomeruli per animal.
Analytical. Systolic blood pressure was obtained by the tail cuff method. Urine and plasma albumin concentrations were measured by rate nephelometry (Beckman Immunochemistry Analyzer II, Beckman Instruments, Palo Alto, California, USA) utilizing specific anti-rat albumin (Cappel Diagnostics, Malvern, Pennsylvania, USA). Plasma total protein concentration was measured with a Lowry assay modified to prevent interference by plasma lipids [12] . The inulin content of plasma, urine, and tubule fluid was assessed by liquid phase scintillation counting.
Calculations. Efferent arteriolar protein concentration (CE) was calculated from the afferent arteriolar protein concentration (CA) and the filtration fraction (if) as: CA 
CE =
A recently derived set of equations relating oncotic pressure to plasma protein concentration in nephrotic rats was used to calculate plasma oncotic pressure [13] . A standard mathematical model was used to derive the glomerular capillary ultrafiltration coefficient, K, and single afferent and efferent arteriolar resistances from these values for oncotic pressure and from measured parameters [14] .
The statistical significance of differences in values of individual parameters in the groups was evaluated by unpaired t-test when two groups were compared and by ANOVA when more than two groups were compared (comparisons of 4-and 6month values in groups 3 and 4). Comparison of blood pressure and albumin excretion rate at different time points in the same group was made by paired t-test. Significance was defined as P <0.05 and results are expressed as mean 1 SEM throughout. Mean values are SEM. Abbreviations used in this table are: wt, weight; Hct, hematocrit; AP, mean arterial pressure; UNaV, urine sodium excretion during micropuncture study; GFR, glomerular filtration rate; SNGFR, single nephron glomerular filtration rate; if, filtration fraction; QA, single nephron plasma flow rate; P, mean glomerular capillary hydraulic pressure; T, proximal tubule hydraulic pressure; P, efferent arteriolar hydraulic pressure; P, mean glomerular transcapillary hydraulic pressure gradient; CA and CE, aiferent and efferent artenolar plasma protein concentration; ITA and ITE, aiferent and efferent arteriolar colloid osmotic pressure; RA and RE, aiferent and efferent arteriolar resistance; RT, total arteriolar resistance; Kf, glomerular capillary ultrafiltration coefficient.
a Values for CEI different from Control, P < 0.05.
Results
Short-term effect of converting enzyme inhibition Systemic blood pressure. The effect of 10 days of converting enzyme inhibitor treatment on systolic blood pressure in ne phrotic rats is depicted in Figure 1 . Baseline systolic blood pressure averaged 134 mm Hg in group 2 and 133 3 mm Hg in group 1. CE! treatment reduced systolic blood pressure to 106 2 mm Hg (P < 0.05). Systolic blood pressure was stable in the untreated nephrotic rats and averaged 135 6 mm Hg at Micropuncture studies. Mean values for body weight, Hct, arterial pressure (AP), left kidney GFR, SNGFR, and the pressures, flows and resistances governing glomerular ultrafiltration in rats in the short-term study are summarized in Table  1 . Mean values for body weight and hematocrit were equivalent in the two groups. Mean arterial pressure AF in untreated nephrotic rats averaged 122 3 mm Hg, whereas the mean arterial pressure in the enalapril-treated rats was significantly lower, averaging 101 2 mm Hg (P <0.05). Despite reduction in renal perfusion pressure, whole kidney GFR was similar in the two groups of nephrotic rats, averaging 1.04 0.11 mI/mm in untreated animals and 1.03 0.04 mI/mm in the enalapriltreated nephrotic animals. Like whole kidney GFR, values for single nephron glomerular filtration rate (SNGFR) were similar in the two experimental groups, averaging 42 3 nI/mm in untreated nephrotic rats and 40 4 ru/mm in enalapril-treated rats. Values for single nephron plasma flow rate, QA' did not differ in the two groups, averaging 157 10 nllmin in untreated rats and 168 16 nI/mm in enalapril-treated rats. The glomerular transcapillary hydraulic pressure difference, zP, averaged 49 2 mm Hg in untreated nephrotic rats. The finding of a high value for zP in rats with untreated adriamycin nephrosis is similar to that of O'Donnell et al [7] but different from that of Fogo et al [10] . In the present study, converting enzyme inhibitor therapy lowered zP to 42 1 mm Hg, a value only slightly above that obtained in normal rats in our laboratory [15] . The reduction in zP seen with enalapril resulted from a fall in the mean glomerular capillary hydraulic pressure (Gc), as values for proximal tubule hydraulic pressure were similar in the two groups. Values for oncotic pressure in afferent arteriolar plasma were also similar in the two groups, averaging 11.7 1.0 mm Hg in untreated rats and 10.8 0.8 mm Hg in enalapril-treated rats. Maintenance of single nephron plasma flow rate despite reduction in mean arterial pressure in enalapril-treated rats indicates that converting enzyme inhibitor therapy caused arteriolar vasodilatation in the nephrotic kidney. Calculated values for afferent arteriolar resistance (RA) and efferent arteriolar resistance (RE) were lower in enalapril-treated rats, but these differences did not reach statistical significance. Values for the glomerular capillary ultrafiltration coefficient (Kf) also did not differ significantly between the two groups.
The effectiveness of converting enzyme inhibition was confirmed by measuring the pressor response to graded boluses of angiotensin I at the close of the micropuncture studies. Figure   3 illustrates the marked reduction in pressure response to angiotensin I observed in enalapril-treated rats.
Chronic effect of converting enzyme inhibition Survival. Untreated group 3 nephrotic rats had a higher mortality than enalapril-treated group 4 rats, but this difference was not significant by chi-square analysis. In group 3, 5 of 26 rats did not survive for four months and two more rats died before six months. In group 4, 3 of 21 rats did not survive for four months. Values for albuminuria and systolic blood pressure in these animals were excluded from analysis.
Systemic blood pressure. As described by Okuda et al [8] , rats with untreated chronic adriamycin-induced nephropathy exhibited a rise in systolic blood pressure (Fig. 4) . Baseline systolic blood pressure in this group averaged 145 3 mm Hg and rose significantly to a mean value of 165 6 mm Hg at four months and a value of 162 5 mm Hg at six months. Systolic blood pressure was significantly lower at each time point in the enalapril-treated nephrotic rats.
Urinary albumin excretion rate. The effect of chronic converting enzyme inhibitor treatment on albumin excretion rate is depicted in Figure 5 . The mean albumin excretion rate in untreated animals was 603 21 mg/day at baseline and rose to 817 43 mg/day at four months and 819 62 mg/day at six months. Despite sustained reduction of blood pressure, enalapril-treated nephrotic rats showed a similar rise in urinary albumin excretion during the study. Albumin excretion rate in this group averaged 589 28 mg/day at baseline and rose to 747 51 mg/day at four months and 773 107 mg/day at six months.
Renal function. Table 2 shows values obtained in groups 3 and 4 at the close of the study. Mean values for body weight were slightly but not significantly greater in the treated rats. Values for serum albumin concentration were similar in each group. As expected, mean arterial pressure in enalapril-treated group 4 rats was reduced significantly below the values observed in untreated group 3 rats at both four and six months. Chronic adriamycin nephropathy in both untreated group 3 rats and in treated group 4 rats was associated with a reduction in glomerular filtration rate as compared to values obtained in group 1 and 2 rats studied earlier in the disease course. In group 3 rats the glomerular filtration rate averaged 0.35 0.08 mI/mm at four months and 0.27 0.07 mllmin at six months as compared to the value of 1.04 0.11 mI/mm obtained in group 1 (P < 0.05 both intervals). Sustained reduction of blood pressure with enalapril limited but did not prevent reduction in glomerular filtration rate. The glomerular filtration rate in group 4 averaged 0.86 0.15 ml/min at four months and 0.68 0.13 mllmin at six months. These values were significantly greater than the values for GFR in untreated group 3 rats at both time intervals but lower than the GFR value of 1.03 0.04 mI/mm obtained in group 2 (P < 0.05 vs. group 2 only at 6 months). Structural alterations. Both untreated and enalapril-treated adriamycin nephrotic rats developed glomerular sclerosis at four and six months, with higher sclerosis scores at six months suggesting progression of glomerular injury with time ( Table 2 ). Partial preservation of GFR in enalapril-treated group 4 rats was associated with lower glomerular sclerosis scores in this group. The reduction in sclerosis score achieved statistical significance at four months (10 5 vs. 29 5, group 4 vs. group 3, P < 0.05) but not at six months (37 8 vs. 54 5, group 4 vs. group 3). Widespread tubulointerstitial changes consisting of tubule dilatation, atrophy, intratubular cast formation, and interstitial fibrosis and inflammation accompanied glomerular sclerotic injury in both groups. The extent of this tubulointerstitial injury was not quantified, but appeared to correlate with the extent of glomerular sclerosis.
Discussion
Recent studies have shown that treatment with a converting enzyme inhibitor to reduce systemic and glomerular capillary pressure largely prevents development of albuminuria and glomerular sclerosis in rats with reduced renal mass and rats with diabetes mellitus [1] [2] [3] . The object of the current study was to assess the effect of converting enzyme inhibitor treatment on the course of renal disease in rats with glomerular injury characterized by heavy proteinuria. Glomerular injury was induced by a single dose of adriamycin, as described by Bertani and coworkers [5, 161 . These investigators have shown that adriamycin, though it has a short half-life, causes irreversible glomerular injury manifested by proteinuria which remains stable over several months.
The initial goal of the current study was to determine whether converting enzyme inhibitor treatment would reduce albuminuria in rats with adriamycin nephrosis. It has recently been suggested that maneuvers which reduce glomerular capillary pressure can reduce permeability to macromolecules in injured glomeruli. In accord with this hypothesis, Yoshioka et al [17] found that acute infusion of acetylcholine reduced both glomerular capillary pressure and protein excretion rate in rats with passive Heymann nephritis. More recently, Hutchison, Schambelan and Kaysen [4] have shown that sustained treatment with converting enzyme inhibitors reduces albuminuria in this disease model. Results of the current study indicate, however, that treatment with the converting enzyme inhibitor enalapnl does not reduce albuminuria in rats with adriamycin nephrosis. Albumin excretion rate remained stable in rats treated with enalapril for 10 days despite significant reduction of both systemic and glomerular capillary pressure. Results of the current short-term study are consistent with the preliminary results of Beukers, Hoedemaeker and Weening [181 showing that captopril treatment does not reduce proteinuria in rats with adriamycin nephrosis. The reason why converting enzyme inhibition reduces proteinuria in passive Heymann nephritis but not in adriamycin nephrosis is unclear. This apparent difference in drug effect cannot be accounted for by differing duration of experimental treatment. Hutchison et al [19] have shown that the decrement in proteinuria observed in rats with Heymann nephritis given enalapril increases over 14 days of drug treatment. In contrast, the current results along with those of Beukers et al [181 indicate that proteinuria in rats with adriamycin nephrosis is not reduced by treatment with converting enzyme inhibitors over periods ranging from eight days to many weeks. Together, these studies suggest that use of converting enzyme inhibitors to lower glomerular capillary pressure cannot be expected to reduce protein excretion in every form of glomerular injury. Of note, available clinical studies indicate that converting enzyme inhibitor therapy lowers proteinuria in some but not all nephrotic patients [20] [21] [22] [23] .
The second goal of the current study was to assess the effect of sustained converting enzyme inhibitor treatment on progression of glomerular injury in rats with adriamycin nephrosis. Morphologic studies carried out at 4 to 12 weeks after administration of adriamycin initially suggested that adriamycininduced glomerular injury does not proceed to glomerular sclerosis [5, 6, 24] . More prolonged studies, however, have since established that rats with adriamycin nephrosis develop widespread glomerular sclerosis over a period of seven to nine months [8] [9] [10] . Okuda et al [8] have shown that progressive glomerular sclerosis in this model is associated with a decline in the glomerular filtration rate and with spontaneous development of hypertension. Results in rats maintained without treatment for five and seven months after adriamycin injection in the current study are consistent with these findings. These rats Mean values SCM. Abbreviations are: Aib, serum albumin concentration; AP, mean arterial pressure; GFR, glomerular filtration rate; LKW, left kidney weight; SS, sclerosis score a P < 0.05, group 4 vs. group 3 at the same time interval b P < 0.05, 6-month value vs. 4-month value for the same group GFR values were not obtained in two group 3 rats at 6 months ing enzyme inhibitor treatment lowered blood pressure and blunted but did not prevent progressive loss of glomerular function in rats with adriamycin nephrosis. The average values for GFR were significantly higher in enalapril treated than in untreated nephrotic rats in our chronic study. However, the values for GFR in both the treated and untreated rats at seven months after adriamycin administration in the chronic study were lower than the values for GFR obtained six weeks after adriamycin administration in the short-term study.
In the present study, reduction of GFR in untreated rats with chronic adriamycin nephrosis was associated with development of widespread glomerular sclerosis, while partial preservation of GFR in enalapril-treated rats was associated with development of less extensive glomerular sclerosis. These associations do not establish that glomerular sclerosis per se is the sole mechanism responsible for reduction of GFR in chronic adriamycin nephrosis. Rats with chronic adriamycin nephrosis also exhibited extensive tubulointerstitial injury. This injury was not quantified in the current study, but could certainly contribute to the reduction in GFR observed in these animals.
Results of the current study show that converting enzyme inhibitor therapy offers only limited protection against progressive loss of renal function in rats with adriamycin nephrosis.
This finding contrasts with previous results in rats with reduced nephron number and rats with diabetes mellitus, in which converting enzyme inhibitor therapy largely prevented development of glomerular sclerosis [1] [2] [3] . The current study suggests that factors other than glomerular capillary hypertension make a major contribution to the progression of renal injury in adriamycin nephrosis. One factor which may contribute to progressive renal injury in nephrosis is persistent heavy proteinuria. Of note, CEI therapy afforded less protection against late glomerular sclerosis in our rats with adriamycin nephrosis than was observed by Anderson et al [25] in a study of rats with puromycin nephrosis. In that study, rats were given a single injection of puromycin in order to induce transient heavy proteinuria. Late development of glomerular sclerosis was attributable to sustained elevation of glomerular capillary pressure following remission of the initial proteinuria. In contrast, we assessed the development of glomerular sclerosis in nephrotic rats with persistent heavy proteinuria. In this regard, our results are comparable to those of Fogo et al [10] who have shown that progressive glomerular sclerosis develops despite maintenance of normal glomerular capillary pressure in rats with persistent proteinuria induced by repeated injection of puromycin. These investigators have further shown that partial protection against the development of progressive glomerular sclerosis by CEI treatment cannot be attributed to reduction of glomerular capillary pressure in this disease model.
The mechanisms responsible for progressive renal injury associated with persistent heavy proteinuria remain to be elucidated. Bertani et al [26] have suggested that heavy proteinuria leads to cast formation with tubular obstruction and subsequent tubulo-interstitial injury. It has further been suggested that the alterations in glomerular capillary wall permeability characteristics which cause proteinuria also promote gradual accumulation of subendothelial hyaline material. Such accumulation is frequently observed in areas of segmental sclerosis and may contribute to the development of glomerular sclerotic injury. Either of these mechanisms could contribute to progressive loss of renal function and glomerular injury when albumin excretion rate remains high, despite reduction of systemic and glomerular capillary pressure by converting enzyme inhibitor treatment.
